Ruitao Lin

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 48

Top Topics

Finite Element Analysis

Drug Administration

Top Venues

Statistics in medicine

Statistical methods in medical research

Biometrical journal. Biometrische Zeitschrift

Pharmaceutical statistics

This page only lists publications with an associated author ORCID identifier.

Publications

Feng Tian, Ruitao Lin, Li Wang, Ying Yuan
A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies. Statistical methods in medical research 33 (6) (2024)
Cheng-Han Yang, Evan Kwiatkowski, J Jack Lee, Ruitao Lin
REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors. Statistics in medicine (2024)
Feng Tian, Ruitao Lin, Li Wang, Ying Yuan
A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies. Statistical methods in medical research (2024)
Cheng-Han Yang, Evan Kwiatkowski, J Jack Lee, Ruitao Lin
REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors. Statistics in medicine 43 (18) (2024)
Xiaohan Chi, Ying Yuan, Zhangsheng Yu, Ruitao Lin
A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical journal. Biometrische Zeitschrift 66 (2) (2024)
Xiaohan Chi, Ying Yuan, Zhangsheng Yu, Ruitao Lin
A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical journal. Biometrische Zeitschrift 66 (2) (2024)
Jingyi Zhang, Ruitao Lin, Xin Chen, Fangrong Yan
Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses. Clinical trials (London, England) (2024)
Cheng-Han Yang, Guanghui Cheng, Ruitao Lin
On the relative conservativeness of Bayesian logistic regression method in oncology dose-finding studies. Pharmaceutical statistics 23 (4) (2024)
Peng Yang, Daniel Li, Ruitao Lin, Bo Huang, Ying Yuan
Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Statistics in medicine (2024)
Feng Tian, Ruitao Lin, Li Wang, Ying Yuan
A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies. Statistical methods in medical research 33 (6) (2024)
Jingyi Zhang, Ruitao Lin, Xin Chen, Fangrong Yan
Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses. Clinical trials (London, England) 21 (3) (2024)
Jingyi Zhang, Ruitao Lin, Xin Chen, Fangrong Yan
Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses. Clinical trials (London, England) 21 (3) (2024)
Cheng-Han Yang, Guanghui Cheng, Ruitao Lin
On the relative conservativeness of Bayesian logistic regression method in oncology dose-finding studies. Pharmaceutical statistics (2024)
Haolun Shi, Ruitao Lin, Xiaolei Lin
Comparative review of novel model-assisted designs for phase I/II clinical trials. Biometrical journal. Biometrische Zeitschrift 66 (4) (2024)
Guanghui Cheng, Ruitao Lin, Liuhua Peng
High-dimensional multivariate analysis of variance via geometric median and bootstrapping. Biometrics 80 (3) (2024)
Cheng-Han Yang, Evan Kwiatkowski, J Jack Lee, Ruitao Lin
REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors. Statistics in medicine 43 (18) (2024)
Feng Tian, Ruitao Lin, Li Wang, Ying Yuan
A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies. Statistical methods in medical research 33 (6) (2024)
Jingyi Zhang, Ruitao Lin, Xin Chen, Fangrong Yan
Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses. Clinical trials (London, England) 21 (3) (2024)
Feng Tian, Ruitao Lin, Li Wang, Ying Yuan
A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies. Statistical methods in medical research 33 (6) (2024)
I-Lin Ho, Chieh-Yuan Li, Fuchenchu Wang, Li Zhao, Jingjing Liu, Er-Yen Yen, Charles A Dyke, Rutvi Shah, Zhaoliang Liu, Ali Osman Çetin, Yanshuo Chu, Francesca Citron, Sergio Attanasio, Denise Corti, Faezeh Darbaniyan, Edoardo Del Poggetto, Sara Loponte, Jintan Liu, Melinda Soeung, Ziheng Chen, Shan Jiang, Hong Jiang, Akira Inoue, Sisi Gao, Angela Deem, Ningping Feng, Haoqiang Ying, Michael P Kim, Virginia Giuliani, Giannicola Genovese, Jianhua Zhang, P Andrew Futreal, Anirban Maitra, Timothy P Heffernan, Linghua Wang, Kim-Anh Do, Ciro Gargiulo Isacco, Giulio F Draetta, Alessandro Carugo, Ruitao Lin, Andrea Viale
Clonal dominance defines metastatic dissemination in pancreatic cancer. Science advances 10 (11) (2024)
Peng Yang, Daniel Li, Ruitao Lin, Bo Huang, Ying Yuan
Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Statistics in medicine 43 (15) (2024)
Xiaohan Chi, Ying Yuan, Zhangsheng Yu, Ruitao Lin
A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical journal. Biometrische Zeitschrift 66 (2) (2024)
Timothy A Lin, Zachary Ryan McCaw, Alex Koong, Christine Lin, Joseph Abi Jaoude, Roshal R Patel, Ramez Kouzy, Molly B El Alam, Alexander D Sherry, Sonal S Noticewala, Clifton David Fuller, Charles R Thomas, Ryan Sun, Jiun-Kae Jack Lee, Ruitao Lin, Ying Yuan, Yu Shyr, Tomer Meirson, Ethan Bernard Ludmir
Proportional Hazards Violations in Phase 3 Cancer Clinical Trials: A Potential Source of Trial Misinterpretation. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Jingyi Zhang, Ruitao Lin, Xin Chen, Fangrong Yan
Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses. Clinical trials (London, England) (2024)
I-Lin Ho, Chieh-Yuan Li, Fuchenchu Wang, Li Zhao, Jingjing Liu, Er-Yen Yen, Charles A Dyke, Rutvi Shah, Zhaoliang Liu, Ali Osman Çetin, Yanshuo Chu, Francesca Citron, Sergio Attanasio, Denise Corti, Faezeh Darbaniyan, Edoardo Del Poggetto, Sara Loponte, Jintan Liu, Melinda Soeung, Ziheng Chen, Shan Jiang, Hong Jiang, Akira Inoue, Sisi Gao, Angela Deem, Ningping Feng, Haoqiang Ying, Michael P Kim, Virginia Giuliani, Giannicola Genovese, Jianhua Zhang, P Andrew Futreal, Anirban Maitra, Timothy P Heffernan, Linghua Wang, Kim-Anh Do, Ciro Gargiulo Isacco, Giulio F Draetta, Alessandro Carugo, Ruitao Lin, Andrea Viale
Clonal dominance defines metastatic dissemination in pancreatic cancer. Science advances 10 (11) (2024)
Xiaohan Chi, Ying Yuan, Zhangsheng Yu, Ruitao Lin
A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical journal. Biometrische Zeitschrift 66 (2) (2024)
Haolun Shi, Ruitao Lin, Xiaolei Lin
Comparative review of novel model-assisted designs for phase I/II clinical trials. Biometrical journal. Biometrische Zeitschrift 66 (4) (2024)
Peng Yang, Daniel Li, Ruitao Lin, Bo Huang, Ying Yuan
Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Statistics in medicine 43 (15) (2024)
Cheng-Han Yang, Evan Kwiatkowski, J Jack Lee, Ruitao Lin
REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors. Statistics in medicine (2024)
Cheng-Han Yang, Guanghui Cheng, Ruitao Lin
On the relative conservativeness of Bayesian logistic regression method in oncology dose-finding studies. Pharmaceutical statistics (2024)
Lilie L Lin, Franklin Wong, Ruitao Lin, Timothy Anthony Yap, Jennifer K Litton
Pharmacodynamic Activity of [ 18 F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2 -Mutated Breast Cancer Receiving Talazoparib. JCO precision oncology 8 (2024)
Jingyi Zhang, Ruitao Lin, Xin Chen, Fangrong Yan
Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses. Clinical trials (London, England) 21 (3) (2024)
Tianlin Xu, Haolun Shi, Ruitao Lin
Bayesian single-to-double arm transition design using both short-term and long-term endpoints. Pharmaceutical statistics (2023)
Peter F Thall, Yong Zang, Andrew Genius Chapple, Ying Yuan, Ruitao Lin, David Marin, Pavlos Msaouel
Novel clinical trial designs with dose optimization to improve long-term outcomes. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Jingyi Zhang, Fangrong Yan, Nolan A Wages, Ruitao Lin
Local continual reassessment methods for dose finding and optimization in drug-combination trials. Statistical methods in medical research (2023)
Xiaohan Chi, Zhangsheng Yu, Ruitao Lin
BOB: Bayesian optimal design for biosimilar trials with co-primary endpoints. Statistics in medicine 41 (26) (2022)
Yanhong Zhou, Ruitao Lin, J Jack Lee, Daniel Li, Li Wang, Ruobing Li, Ying Yuan
TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Statistics in medicine 41 (11) (2022)
Yanhong Zhou, Ruitao Lin, Jiun-Kae Jack Lee
The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials. Pharmaceutical statistics 20 (6) (2021)
Amanda Olson, Ruitao Lin, David Marin, Hind Rafei, Mustafa H Bdaiwi, Peter F Thall, Rafet Basar, Ala Abudayyeh, Pinaki Banerjee, Fleur M Aung, Indresh Kaur, Glorette Abueg, Sheetal Rao, Roy F Chemaly, Victor Mulanovich, Gheath Al-Atrash, Amin M Alousi, Borje S Andersson, Paolo Anderlini, Qaiser Bashir, Karla M Castro, May Daher, Isabel M Galvan, Chitra Hosing, Jin S Im, Roy B Jones, Partow Kebriaei, Issa F Khouri, Rohtesh S Mehta, Jeffrey Molldrem, Yago L Nieto, Betül Oran, Sairah A Ahmed, Muzaffar Qazilbash, Gabriela Rondon, Neeraj Saini, Bryan Spencer, Samer Srour, Dominique Washington, Melissa Barnett, Richard E Champlin, Elizabeth J Shpall, Katayoun Rezvani
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (24) (2021)
Ruitao Lin, Kc Gary Chan, Haolun Shi
A unified Bayesian framework for exact inference of area under the receiver operating characteristic curve. Statistical methods in medical research 30 (10) (2021)
Ruitao Lin, Guosheng Yin, Haolun Shi
Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials. Biostatistics (Oxford, England) (2021)
Haolun Shi, Jiguo Cao, Ying Yuan, Ruitao Lin
uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials. Statistics in medicine 40 (11) (2021)
Yeonhee Park, Ruitao Lin
Discussion on "Predictively consistent prior effective sample sizes," by Beat Neuenschwander, Sebastian Weber, Heinz Schmidli, and Anthony O'Hagan. Biometrics 76 (2) (2020)
Ruitao Lin, Yanhong Zhou, Fangrong Yan, Daniel Li, Ying Yuan
BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO precision oncology 4 (2020)
Ruitao Lin, Peter F Thall, Ying Yuan
An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. Biometrics 76 (1) (2019)
Ruitao Lin
Bayesian optimal interval design with multiple toxicity constraints. Biometrics 74 (4) (2018)
Ruitao Lin, Guosheng Yin
Uniformly most powerful Bayesian interval design for phase I dose-finding trials. Pharmaceutical statistics 17 (6) (2018)
Ruitao Lin, Guosheng Yin
STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials. Statistics in medicine 36 (26) (2017)